This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Compugen Discloses Experimental Results For Novel Checkpoint Candidate For Cancer Immunotherapy And Discovery Of Two New Candidates

Compugen Ltd. (NASDAQ:  CGEN) disclosed today positive experimental results for CGEN-15052, a novel immune checkpoint candidate for cancer immunotherapy, which in several experimental settings demonstrated robust inhibition of T cell activation, both as a membrane protein and as an Fc fusion protein. Initial testing of human cancer tissue samples with a polyclonal antibody indicated that CGEN-15052 is expressed in multiple epithelial cancers, with particularly high expression in lung cancer samples. These positive findings support CGEN-15052’s involvement in tumor immunology and its potential as a target for cancer immunotherapy.

Compugen also disclosed today the predictive discovery of two new B7-like immune checkpoint candidates, increasing to eleven the total number of such candidates discovered to date by the Company in this area of high medical and pharmaceutical industry interest. The predictive discovery of these two new immune checkpoint candidates was accomplished utilizing the same predictive models and algorithms that led to the identification of nine novel candidates in the Company’s earlier discovery efforts, but followed enhancement of these models and algorithms through incorporation of additional information obtained from those initial efforts.

Dr. Anat Cohen Dayag, Compugen’s President and CEO, stated, “Our disclosures today of successful experimental results for another of our initial nine checkpoint discoveries, and of new discoveries from a follow-on run utilizing the same predictive models, but enhanced with information from such initial discovery efforts, provide excellent validation of the value and uniqueness of our predictive discovery capabilities. After more than a decade of extensive multidisciplinary research to gain deeper understanding of key biological phenomena, providing the basis for the creation of our predictive models and discovery platforms, it is very rewarding to see these promising results from our first focused use of this powerful capability.”

About Immune Checkpoints

Immune checkpoints are inhibitory receptors and their ligands, which are crucial for the maintenance of self-tolerance (that is, the prevention of autoimmunity) and for the protection of tissues from damage when the immune system is responding to pathogenic infection or other injuries. These immune checkpoints, which are "highjacked" by tumors to block the ability of the immune system to destroy the tumor (immune resistance), have lately emerged as "game changers" and promising targets for cancer immunotherapy. Therapeutic blockade of immune checkpoints can boost anti-tumor immunity, enabling the patient’s immune system to recognize and attack the tumor cells, and mount durable anti-tumor responses and tumor destruction. The blockade of immune checkpoints unleashes the potential of the anti-tumor immune response in a fashion that is transforming cancer therapeutics. Checkpoint-blocking antibodies have lately demonstrated impressive clinical benefits and long-term survival, even for end-stage patients, raising hopes that this novel approach will lead to effective therapeutic strategies and valuable additions in the fight against cancer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs